Markus A. Seeger

Markus A. Seeger

Auto-generated profile, based on publicly available information

Markus A. Seeger

Institute of Medical Microbiology, University of Zurich

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2006 in Science
Verified
Journal Article
Open access
PDF file
MSMarkus A. Seeger
Markus A. Seeger
ASAndré Schiefner
André Schiefner
TEThomas Eicher
Thomas Eicher
FVFrançois Verrey
François Verrey
KDKay Diederichs
Kay Diederichs
KPKlaas M. Pos
Klaas M. Pos
The AcrA/AcrB/TolC complex spans the inner and outer membranes of Escherichia coli and serves as its major drug-resistance pump. Driven by the proton motive force, it mediates the efflux of bile salts, detergents, organic solvents, and many structurally unrelated antibiotics. Here, we report a crystallographic structure of trimeric AcrB determined at 2.9 and 3.0 angstrom resolution in space groups that allow asymmetry of the monomers. This structure reveals three different monomer conformations representing consecutive states in a transport cycle. The structural data imply an alternating access mechanism and a novel peristaltic mode of drug transport by this type of transporter.

26 March 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
TEThomas Eicher
Thomas Eicher
HCHi-Jea Cha
Hi-Jea Cha
MSMarkus A. Seeger
Markus A. Seeger
LBLorenz Brandstätter
Lorenz Brandstätter
JEJasmin El-Delik
Jasmin El-Delik
KPKlaas Martinus Pos
Klaas Martinus Pos
AcrAB-TolC is the major efflux protein complex in Escherichia coli extruding a vast variety of antimicrobial agents from the cell. The inner membrane component AcrB is a homotrimer, and it has been postulated that the monomers cycle consecutively through three conformational stages designated loose (L), tight (T), and open (O) in a concerted fashion. Binding of drugs has been shown at a periplasmic deep binding pocket in the T conformation. The initial drug-binding step and transport toward this drug-binding site has been elusive thus far. Here we report high resolution structures (1.9–2.25 Å) of AcrB/designed ankyrin repeat protein (DARPin) complexes with bound minocycline or doxorubicin. In the AcrB/doxorubicin cocrystal structure, binding of three doxorubicin molecules is apparent, with one doxorubicin molecule bound in the deep binding pocket of the T monomer and two doxorubicin molecules in a stacked sandwich arrangement in an access pocket at the lateral periplasmic cleft of the L monomer. This access pocket is separated from the deep binding pocket apparent in the T monomer by a switch-loop. The localization and conformational flexibility of this loop seems to be important for large substrates, because a G616N AcrB variant deficient in macrolide transport exhibits an altered conformation within this loop region. Transport seems to be a stepwise process of initial drug uptake in the access pocket of the L monomer and subsequent accommodation of the drug in the deep binding pocket during the L to T transition to the internal deep binding pocket of the T monomer.

25 March 2012 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
MHMichael Hohl
Michael Hohl
CBChristophe Briand
Christophe Briand
MGMarkus G Grütter
Markus G Grütter
MSMarkus A Seeger
Markus A Seeger

24 May 2018 in eLife
Verified
Journal Article
Open access
IZIwan Zimmermann
Iwan Zimmermann
PEPascal Egloff
Pascal Egloff
CHCedric Aj Hutter
Cedric Aj Hutter
FAFabian M Arnold
Fabian M Arnold
PSPeter Stohler
Peter Stohler
MSMarkus A Seeger
Markus A Seeger
Mechanistic and structural studies of membrane proteins require their stabilization in specific conformations. Single domain antibodies are potent reagents for this purpose, but their generation relies on immunizations, which impedes selections in the presence of ligands typically needed to populate defined conformational states. To overcome this key limitation, we developed an in vitro selection platform based on synthetic single domain antibodies named sybodies. To target the limited hydrophilic surfaces of membrane proteins, we designed three sybody libraries that exhibit different shapes and moderate hydrophobicity of the randomized surface. A robust binder selection cascade combining ribosome and phage display enabled the generation of conformation-selective, high affinity sybodies against an ABC transporter and two previously intractable human SLC transporters, GlyT1 and ENT1. The platform does not require access to animal facilities and builds exclusively on commercially available reagents, thus enabling every lab to rapidly generate binders against challenging membrane proteins.

19 September 2014 in eLife
Verified
Journal Article
Open access
TEThomas Eicher
Thomas Eicher
MSMarkus A Seeger
Markus A Seeger
CAClaudio Anselmi
Claudio Anselmi
WZWenchang Zhou
Wenchang Zhou
LBLorenz Brandstätter
Lorenz Brandstätter
KPKlaas Martinus Pos
Klaas Martinus Pos
Membrane transporters of the RND superfamily confer multidrug resistance to pathogenic bacteria, and are essential for cholesterol metabolism and embryonic development in humans. We use high-resolution X-ray crystallography and computational methods to delineate the mechanism of the homotrimeric RND-type proton/drug antiporter AcrB, the active component of the major efflux system AcrAB-TolC in Escherichia coli, and one most complex and intriguing membrane transporters known to date. Analysis of wildtype AcrB and four functionally-inactive variants reveals an unprecedented mechanism that involves two remote alternating-access conformational cycles within each protomer, namely one for protons in the transmembrane region and another for drugs in the periplasmic domain, 50 Å apart. Each of these cycles entails two distinct types of collective motions of two structural repeats, coupled by flanking α-helices that project from the membrane. Moreover, we rationalize how the cross-talk among protomers across the trimerization interface might lead to a more kinetically efficient efflux system.

8 April 2020 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
IZIwan Zimmermann
Iwan Zimmermann
PEPascal Egloff
Pascal Egloff
CHCedric A. J. Hutter
Cedric A. J. Hutter
BKBenedikt T. Kuhn
Benedikt T. Kuhn
PBPhilipp Bräuer
Philipp Bräuer
MSMarkus A. Seeger
Markus A. Seeger